AMAG Pharma (AMAG) Misses Q2 EPS, Revs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
AMAG Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Corporate Update
August 6, 2020 7:00 AM EDTFinancial guidance reissued to include EBITDA-positive projection for second-half 2020
Strategic shift and momentum build through recent business development activities
Brian Piekos promoted to Chief Financial Officer
Conference call scheduled for 8:00 a.m. ET today
WALTHAM, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today reported unaudited consolidated financial results for the second quarter ended June 30, 2020. The company reported total revenues for the second quarter of 2020 of $52.8 million, including revenue of $29.6 million from Feraheme® (ferumoxytol injection) and... More



